Calidi Biotherapeutics, Inc.
CLDI
$1.49
-$0.01-0.73%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -35.91% | -36.99% | -32.99% | -19.31% | -1.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.18% | -32.43% | -33.78% | -24.89% | -1.75% |
| Operating Income | 28.18% | 32.43% | 33.78% | 24.89% | 1.75% |
| Income Before Tax | 23.40% | 13.75% | 33.14% | 23.99% | 8.51% |
| Income Tax Expenses | 150.00% | -55.00% | -18.75% | -12.50% | -50.00% |
| Earnings from Continuing Operations | 23.35% | 13.79% | 33.13% | 23.98% | 8.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,266.67% | -- | -- | -- | -- |
| Net Income | 24.08% | 14.60% | 33.61% | 24.21% | 8.59% |
| EBIT | 28.18% | 32.43% | 33.78% | 24.89% | 1.75% |
| EBITDA | 29.40% | 33.71% | 36.03% | 27.19% | 3.80% |
| EPS Basic | 87.45% | 82.33% | 87.53% | 82.92% | 80.15% |
| Normalized Basic EPS | 88.47% | 80.65% | 88.94% | 83.96% | 83.48% |
| EPS Diluted | 87.45% | 82.33% | 87.53% | 82.92% | 80.15% |
| Normalized Diluted EPS | 88.47% | 80.65% | 88.94% | 83.96% | 83.48% |
| Average Basic Shares Outstanding | 569.85% | 510.52% | 488.99% | 374.84% | 402.89% |
| Average Diluted Shares Outstanding | 569.85% | 510.52% | 488.99% | 374.84% | 402.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |